Blue Leopard Genomic Essentials Profile
Key Indicators
- Authorised Capital ₹ 7.00 Cr
as on 16-01-2025
- Paid Up Capital ₹ 4.43 Cr
as on 16-01-2025
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 901125.83%
(FY 2023)
- Profit 36.80%
(FY 2023)
- Ebitda -454.09%
(FY 2023)
- Net Worth -1.23%
(FY 2023)
- Total Assets 203.35%
(FY 2023)
About Blue Leopard Genomic Essentials
The Corporate was formerly known as Blue Leopard Enterprises Private Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.00 Cr and a paid-up capital of Rs 4.43 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sneha Datar, Vineet Datta, Swati Deshpande, and One other member serve as directors at the Company.
- CIN/LLPIN
U73100MH2017PTC298233
- Company No.
298233
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Aug 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nashik, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Blue Leopard Genomic Essentials?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sneha Datar  | Director | 11-Jul-2023 | Current |
Vineet Datta  | Director | 26-Dec-2018 | Current |
| Swati Deshpande | Director | 26-Dec-2018 | Current |
| Dadasaheb Bhausaheb | Director | 26-Dec-2018 | Current |
Financial Performance of Blue Leopard Genomic Essentials.
Blue Leopard Genomic Essentials Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 901125.83% increase. The company also saw a substantial improvement in profitability, with a 36.8% increase in profit. The company's net worth dipped by a decrease of 1.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Blue Leopard Genomic Essentials?
In 2023, Blue Leopard Genomic Essentials had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Datar Cancer Genetics Private LimitedActive 32 years 6 monthsSneha Datar and Swati Deshpande are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Blue Leopard Genomic Essentials?
Unlock and access historical data on people associated with Blue Leopard Genomic Essentials, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Blue Leopard Genomic Essentials, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Blue Leopard Genomic Essentials's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
